News & Events
BRENTWOOD, Tenn. (August 5, 2014) – PathGroup, a leading provider of anatomic, clinical and molecular pathology services, and Cancer Clinics of Excellence (CCE), a national network of community-based oncology practices, is pleased to announce a newly formed partnership utilizing PathGroup’s versatile genomic profiling platform, SmartGenomics™, to further identify pharmacotherapeutic targets for patients within the CCE network.
For Full Release, please CLICK HERE
This will take effect August 4, 2014
Overview and Clinical Utility:
To improve performance and sensitivity of the Toxoplasma assay, PathGroup Labs will begin testing by Chemiluminescent Immunoassay for IgM Antibodies. The serological diagnosis of acute toxoplasmosis allows adequate treatment which reduces the risks of the disease both in immunocompromised patients and pregnant women.
Click Here to read more.
This will take effect June 23, 2014
Overview and Clinical Utility:
Effective June 23, 2014, PathGroup will be insourcing maternal serum screening, integrated, to evaluate the risk for Down’s syndrome, Trisomy 18 and Open Spina Bifida. First specimen should be collected in the first trimester between 11 weeks and 13 weeks 6 days and Crown-Rump length (CRL) must be 4.2-8.5 cm. The second specimen should be collected in second trimester between 15 weeks and 18 weeks 6 days (optimal collection time frame) but can be collected until 21 weeks 6 days. Preliminary report after the first specimen will only have PAPP-A with final interpretation pending second specimen submission.
Click Here to read more.
This will take effect June 9, 2014
Overview and Clinical Utility:
PathGroup is pleased to announce the immediate availability of the FDA-approved APTIMA Trichomonas vaginalis detection assay by Hologic. Trichomonas vaginalis is the most common curable sexually transmitted disease (STD) agent in the United States, with an estimated 7.4 million new cases occurring annually. Infections in women cause vaginitis, urethritis, and cervicitis. Discharge and small hemorrhagic lesions may be present in the genitourinary tract.
Click Here to read more.
This will take effect May 19, 2014
Overview and Clinical Utility:
Effective May 19, 2014, PathGroup will implement in-house testing for Urine Protein Electrophoresis (UPE). Protein electrophoresis is a well-established technique routinely used for the screening of protein abnormalities. Urine protein electrophoretic patterns can classify proteinuria as glomerular, tubular, combined, stress or normal.
Click Here to read more.
Thomson Reuters, PathGroup and GenoSpace collaborate to deliver advanced personalized medicine assays and reports to oncologists.
CAMBRIDGE, MA, – (May 8, 2014) — GenoSpace today announced that the company was named a Best of Show grand prize winner at the 2014 Bio-IT World Conference and Expo. GenoSpace for Clinical™ was recognized in the Web-Based Services and Software category for its comprehensive suite of offerings supporting genomic medicine.
Click Here to read the full article.
This will take effect April 28, 2014
Overview and Clinical Utility:
PathGroup Labs will begin confirmatory testing for a positive HIV screen utilizing the Bio-Rad MultiSpot HIV1/HIV2 discriminatory assay and will discontinue confirmatory testing by Western Blot effective April 28, 2014. It is strongly recommended that patients whose positive screen is followed by a negative confirmatory assay be tested by Nucleic Acid Testing.
Click Here to read more.
HIV Confirmation Screening Algorithm
This will take effect April 14, 2014
Overview and Clinical Utility:
Effective April 14, 2014, PathGroup will change methodologies for the celiac disease panel (tissue transglutaminase and deaminated gliadin IgA and IgG). Methodology will change from enzyme immunoassay to multiplex flow immunoassay.
Click Here to read more.
This will take effect April 14, 2014
Overview and Clinical Utility:
Effective April 14, 2014, PathGroup will be changing methodology for cardiolipin antibodies IgA, IgG and IgM from enzyme immunoassay to multiplex flow immunoassay. We will also insource Beta-2 Glycoprotein IgA, IgG and IgM using multiplex flow immunoassay.
Click Here to read more.
This will take effect March 24, 2014
Overview and Clinical Utility:
Effective March 24, 2014, PathGroup will insource the maternal screen for Open Spina Bifida Only with a 2.5 MoM (multiple of the median) cut-off. This screen is used to evaluate the risk for open spina bifida. Specimen should be collected in the second trimester between 14 weeks and 21 weeks 6 days.
Click Here to read more.
